ClinicalTrials.gg
CompletedNCT06169124Updated Nov 3, 2026Results posted

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

A Phase 2 interventional study of Biospecimen Collection and Chest Radiography in Adult Ovarian Granulosa Cell Tumor, sponsored by National Cancer Institute (NCI). Completed at 66 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This phase II trial tests how well darolutamide in combination with leuprolide acetate and exemestane works in treating patients with ovarian granulosa cell tumors that have come back after a period of improvement (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Leuprolide acetate is in a class of medications called gonadotropin-releasing hormone agonists. It works by decreasing the amount of certain hormones in the body. Exemestane is in a class of medications called aromatase inhibitors which has anti-estrogen and anticancer activities. Exemestane binds to and inhibits the enzyme aromatase, thereby blocking the conversion of androgens to estrogens. This lowers estrogen levels in the blood circulation causing the tumor cells to grow more slowly or stop growing completely. The combination of darolutamide, leuprolide acetate, and exemestane may be an effective approach to shrinking or stabilizing recurrent ovarian granulosa cell tumors or preventing them from coming back.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the objective response rate of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type granulosa cell tumors of the ovary (AGCT).

SECONDARY OBJECTIVES:

I. To determine duration of response of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type granulosa cell tumors of the ovary (AGCT).

II. To determine progression-free survival of darolutamide, leuprolide acetate, and exemestane when used in recurrent adult-type granulosa cell tumors of ovary (AGCT).

III. To determine overall survival of darolutamide, leuprolide acetate, and exemestane when used in recurrent adult-type granulosa cell tumors of ovary (AGCT).

IV. To elucidate the toxicities of darolutamide, leuprolide acetate, and exemestane when used in recurrent adult-type granulosa cell tumors of ovary (AGCT).

EXPLORATORY OBJECTIVE:

I. To determine biomarkers predictive of response to darolutamide, leuprolide acetate, and exemestane.

OUTLINE:

Patients receive exemestane orally (PO) once daily (QD) and darolutamide PO twice daily (BID) starting on days -14 to -7 prior to cycle 1, day 1 (C1D1) and then on days 1-28 of each cycle. Patients receive leuprolide acetate intramuscularly (IM) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo chest computed tomography (CT) or chest x-ray and CT, magnetic resonance imaging (MRI), or positron emission tomography (PET)/CT as well as blood sample collection throughout the study. Patients undergo collection of archived tissue during screening.

Upon completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

02

Conditions studied

  • Adult Ovarian Granulosa Cell Tumor
03

In context

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physicians should consider the following when evaluating if the patient is appropriate for this protocol:

    • Patients must have adequate health that permits completion of the study requirements and required follow up
    • For patients with known (HIV), virus (HBV), and/or virus (HCV) infection:

      • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
      • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
      • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
    • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial

In addition:

  • The effects of the combination of darolutamide, leuprolide acetate, and exemestane on the developing human fetus are unknown. For this reason, and because androgen receptor inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, participants of must agree to use adequate (hormonal or barrier method of birth control; abstinence) during study therapy and for 1 month following the completion of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately

    • Submission of tissue is required. Investigators should check with their pathology department regarding release of tissue before approaching patients about participation in the trial
    • confirmed diagnosis of recurrent adult-type granulosa cell tumor
    • Patient must have . Measurable disease is defined in the protocol per (RECIST) 1.1 criteria. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT or MRI. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI
    • Patient must have had ≥1 treatment regimen
    • Subject must have progressed on an aromatase inhibitor (letrozole, exemestane, anastrozole) in a prior treatment line
    • Age ≥ 18 years
    • (ECOG) performance status of ≤ 2
    • Not pregnant and not nursing
    • (ANC) ≥ 1,500 cells/mm\^3
    • ≥ 100,000 cells/mm\^3
    • ≥ 8 g/dl
    • (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula
    • Total ≤ 1.5 x institutional (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
    • (AST) and alanine aminotransferase (ALT) ≤ 1.5 x institutional ULN
    • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better
    • No active infection requiring parenteral antibiotics
    • Patients with current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube
    • The patient or a legally authorized representative must provide study-specific prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with AR inhibitors
  • Known to the study drugs or their ingredients
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment (exemestane, darolutamide, leuprolide acetate)

    Patients receive exemestane PO QD and darolutamide PO BID starting on days -14 to -7 prior to C1D1 and then on days 1-28 of each cycle. Patients receive leuprolide acetate IM on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo chest CT or chest x-ray and CT, MRI, or PET/CT as well as blood sample collection throughout the study. Patients undergo collection of archived tissue during screening.

    Procedure: Biospecimen Collection · Procedure: Chest Radiography · Procedure: Computed Tomography · Drug: Darolutamide · Drug: Exemestane · Drug: Leuprolide Acetate · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography

Interventions

  • ProcedureBiospecimen Collection

    Undergo archived tissue and blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: Chest X-ray

  • ProcedureComputed Tomography

    Undergo CT and/or PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given PO

    Also known as: Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, ODM201

  • Given PO

    Also known as: Aromasin, FCE-24304

  • Given IM

    Also known as: A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Defined as a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Exact 95% confidence limits, accounting for interim analysis, will be provided in the final report.

    Time frame: Within 9 months of initiating study treatment

Secondary outcomes

  1. Duration of Response

    The duration of overall response is measured from the time measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that recurrence or progressive disease is objectively documented. Only one patient experienced a partial response (PR) within the 9-month response window. Therefore the 95% confidence interval for the duration of response was not estimated.

    Time frame: Within 9 months of initiating study treatment

  2. Progression-free Survival (PFS)

    Progression-free survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact with known progression-free status if neither progression nor death has occurred. Patients with no follow-up will be censored 1 day after enrollment. Will be graphed using Kaplan-Meier methods. Median PFS will be estimated with corresponding 95% confidence intervals.

    Time frame: up to 22 months

  3. Overall Survival (OS)

    Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. Patients with no follow-up will be censored 1 day after enrollment. Will be graphed using Kaplan-Meier methods. Median OS will be estimated with corresponding 95% confidence intervals. The OS was not reached due to the study early termination for futility. Thus the death rate was reported instead of survival time.

    Time frame: up to 22 months

  4. Incidence of Adverse Events

    Common Terminology Criteria for Adverse Events version 5 will be used to grade and categorize adverse events. Safety will be assessed beginning with the initial dose of any treatment. Descriptive statistics, including frequencies of maximum grade of adverse events by term and category will be reported. Adverse events categorized as grade 5 will be individually reported.

    Time frame: Adverse Events were assessed up to 9 months, All Cause Mortality was assessed up to 22 months.

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Started17
Completed16
Not completed1
Withdrew: Not initiating leuprolide actate1

Outcome measures

PrimaryObjective Response Rate (ORR)

Defined as a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Exact 95% confidence limits, accounting for interim analysis, will be provided in the final report.

Time frame:
Within 9 months of initiating study treatment
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Objective Response Rate (ORR)1
SecondaryDuration of Response

The duration of overall response is measured from the time measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that recurrence or progressive disease is objectively documented. Only one patient experienced a partial response (PR) within the 9-month response window. Therefore the 95% confidence interval for the duration of response was not estimated.

Time frame:
Within 9 months of initiating study treatment
Reported as:
Number · months
Duration of Response
monthsTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Duration of Response8.8
SecondaryProgression-free Survival (PFS)

Progression-free survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact with known progression-free status if neither progression nor death has occurred. Patients with no follow-up will be censored 1 day after enrollment. Will be graphed using Kaplan-Meier methods. Median PFS will be estimated with corresponding 95% confidence intervals.

Time frame:
up to 22 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Progression-free Survival (PFS)8.5 (3.1 to 12.0)
SecondaryOverall Survival (OS)

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. Patients with no follow-up will be censored 1 day after enrollment. Will be graphed using Kaplan-Meier methods. Median OS will be estimated with corresponding 95% confidence intervals. The OS was not reached due to the study early termination for futility. Thus the death rate was reported instead of survival time.

Time frame:
up to 22 months
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Overall Survival (OS)5
SecondaryIncidence of Adverse Events

Common Terminology Criteria for Adverse Events version 5 will be used to grade and categorize adverse events. Safety will be assessed beginning with the initial dose of any treatment. Descriptive statistics, including frequencies of maximum grade of adverse events by term and category will be reported. Adverse events categorized as grade 5 will be individually reported.

Time frame:
Adverse Events were assessed up to 9 months, All Cause Mortality was assessed up to 22 months.
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
Incidence of Adverse Events17

Adverse events

Collected over Adverse Events were assessed up to 9 months, All-Cause Mortality was assessed up to 22 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Exemestane, Darolutamide, Leuprolide Acetate)5/17 (29.4%)7/17 (41.2%)10/17 (58.8%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
ConstipationGastrointestinal Disorders2/17
VomitingGastrointestinal Disorders2/17
AnemiaBlood And Lymphatic System Disorders1/17
Rectal PainGastrointestinal Disorders1/17
Small Intestinal ObstructionGastrointestinal Disorders1/17
NauseaGastrointestinal Disorders1/17
Abdominal PainGastrointestinal Disorders1/17
Disease ProgressionGeneral Disorders And Administration Site Conditions1/17
Investigations - OtherInvestigations1/17
Creatinine IncreasedInvestigations1/17
Most frequent other events
Showing 10 of 75
Most frequent other events
EventTreatment (Exemestane, Darolutamide, Leuprolide Acetate)
NauseaGastrointestinal Disorders9/17
FatigueGeneral Disorders And Administration Site Conditions8/17
AnemiaBlood And Lymphatic System Disorders7/17
Abdominal PainGastrointestinal Disorders6/17
VomitingGastrointestinal Disorders5/17
ConstipationGastrointestinal Disorders4/17
Upper Respiratory InfectionInfections And Infestations4/17
HypokalemiaMetabolism And Nutrition Disorders4/17
HypertensionVascular Disorders4/17
Hot FlashesVascular Disorders4/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
Median58 (30 to 87)
Age, Customized
Age, Customized(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
Age Category — 30-391
Age Category — 40-494
Age Category — 50-595
Age Category — 60-694
Age Category — 70-792
Age Category — 80-891
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
Female17
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White12
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
United States17
Stage
Stage(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
I8
II2
III3
IV3
NOT REPORTED1
Prior Hormone Therapy (HT)
Prior Hormone Therapy (HT)(Participants)Treatment (Exemestane, Darolutamide, Leuprolide Acetate)
Count of participants17

1 further baseline measures are reported on the registry.

08

Study locations

66 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Helen F Graham Cancer Center
    Newark, Delaware 19713, United States
  • Medical Oncology Hematology Consultants PA
    Newark, Delaware 19713, United States
  • Saint Alphonsus Cancer Care Center-Boise
    Boise, Idaho 83706, United States
  • Saint Alphonsus Cancer Care Center-Caldwell
    Caldwell, Idaho 83605, United States
  • Kootenai Health - Coeur d'Alene
    Coeur d'Alene, Idaho 83814, United States
  • Saint Alphonsus Cancer Care Center-Nampa
    Nampa, Idaho 83687, United States
  • Kootenai Clinic Cancer Services - Post Falls
    Post Falls, Idaho 83854, United States
  • Kootenai Clinic Cancer Services - Sandpoint
    Sandpoint, Idaho 83864, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Carle at The Riverfront
    Danville, Illinois 61832, United States
  • Northwestern Medicine Cancer Center Kishwaukee
    DeKalb, Illinois 60115, United States
  • Carle Physician Group-Effingham
    Effingham, Illinois 62401, United States
  • Northwestern Medicine Cancer Center Delnor
    Geneva, Illinois 60134, United States
  • Northwestern Medicine Grayslake Outpatient Center
    Grayslake, Illinois 60030, United States
  • Northwestern Medicine Lake Forest Hospital
    Lake Forest, Illinois 60045, United States
  • Carle Physician Group-Mattoon/Charleston
    Mattoon, Illinois 61938, United States
  • Northwestern Medicine Orland Park
    Orland Park, Illinois 60462, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Northwestern Medicine Cancer Center Warrenville
    Warrenville, Illinois 60555, United States
  • Ascension Saint Vincent Indianapolis Hospital
    Indianapolis, Indiana 46260, United States
  • University of Iowa/Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • MaineHealth Maine Medical Center- Scarborough
    Scarborough, Maine 04074, United States
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Ann Arbor, Michigan 48106, United States
  • University of Michigan Rogel Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Bronson Battle Creek
    Battle Creek, Michigan 49017, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton
    Brighton, Michigan 48114, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Canton
    Canton, Michigan 48188, United States
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
    Chelsea, Michigan 48118, United States
  • Cancer Hematology Centers - Flint
    Flint, Michigan 48503, United States
  • Genesee Hematology Oncology PC
    Flint, Michigan 48503, United States
  • Genesys Hurley Cancer Institute
    Flint, Michigan 48503, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
    Grand Rapids, Michigan 49503, United States
  • Trinity Health Grand Rapids Hospital
    Grand Rapids, Michigan 49503, United States
  • Bronson Methodist Hospital
    Kalamazoo, Michigan 49007, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
  • Beacon Kalamazoo Cancer Center
    Kalamazoo, Michigan 49009, United States
  • Trinity Health Saint Mary Mercy Livonia Hospital
    Livonia, Michigan 48154, United States
  • Trinity Health Muskegon Hospital
    Muskegon, Michigan 49444, United States
  • Cancer and Hematology Centers of Western Michigan - Norton Shores
    Norton Shores, Michigan 49444, United States
  • Corewell Health Reed City Hospital
    Reed City, Michigan 49677, United States
  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
    Saint Joseph, Michigan 49085, United States
  • Munson Medical Center
    Traverse City, Michigan 49684, United States
  • University of Michigan Health - West
    Wyoming, Michigan 49519, United States
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    Ypsilanti, Michigan 48197, United States
  • Mercy Hospital Saint Louis
    St Louis, Missouri 63141, United States
  • Community Hospital of Anaconda
    Anaconda, Montana 59711, United States
  • Billings Clinic Cancer Center
    Billings, Montana 59101, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
  • Benefis Sletten Cancer Institute
    Great Falls, Montana 59405, United States
  • Community Medical Center
    Missoula, Montana 59804, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Carolinas Medical Center/Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
  • Atrium Health Cabarrus/LCI-Concord
    Concord, North Carolina 28025, United States
  • Miami Valley Hospital South
    Centerville, Ohio 45459, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • ProMedica Flower Hospital
    Sylvania, Ohio 43560, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Saint Alphonsus Cancer Care Center-Ontario
    Ontario, Oregon 97914, United States
  • Legacy Good Samaritan Hospital and Medical Center
    Portland, Oregon 97210, United States
  • Legacy Meridian Park Hospital
    Tualatin, Oregon 97062, United States
  • Legacy Salmon Creek Hospital
    Vancouver, Washington 98686, United States
  • West Virginia University Charleston Division
    Charleston, West Virginia 25304, United States
  • ThedaCare Regional Cancer Center
    Appleton, Wisconsin 54911, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Hopp EE, Enserro D, Campos S, Chitiyo V, Huang G, Lankes H, Crane EK, Hoekstra A, Siedel J, Richardson DL, Aghajanian C, Rader JS, Covens A. A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor. Gynecol Oncol. 2026 Aug 10;212:98-105. doi: 10.1016/j.ygyno.2026.07.017. Online ahead of print. PubMed 42574969 ↗
  • Erfani H, Martynova A, Matsuzaki S, Matsuo K, Roman LD, Sood AK, Kurnit KC, Westin SN. Androgen receptor as a therapeutic target in endometrial cancer: a narrative review. Int J Gynecol Cancer. 2026 Jun;36(6):104698. doi: 10.1016/j.ijgc.2026.104698. Epub 2026 Apr 11. PubMed 42070324 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Feb 2026, 24 months.

Results were first posted in Nov 2026, 8 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Sep 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 13, 2023
StartActual
Feb 8, 2024
Primary completionActual
Feb 10, 2026
CompletionActual
Sep 28, 2026was Jul 2027
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 3, 2026
Results
Results posted
posted Nov 3, 2026
Study completion
Jul 24, 2027→Sep 28, 2026 (actual)
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective response rateResponse Rate (ORR)Time frame: Within 9 months of initiating study treatment
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42574969 ↗
Nov 3, 2026
Secondary outcomes
4 edited, 1 removed
What changed in the outcomes
  • EditedDuration of responseResponseTime frame: From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years → Within 9 months of initiating study treatment
  • EditedProgression-free survivalSurvival (PFS)Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact with known progression free status if neither progression nor death has occurred, assessed up to 5 years → up to 22 months
  • EditedOverall survivalSurvival (OS)Time frame: From study entry to time of death or the date of last contact, assessed up to 5 years → up to 22 months
  • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 5 years → Adverse Events were assessed up to 9 months, All Cause Mortality was assessed up to 22 months.
  • Removedother outcomeBiomarkers predictive of responseTime frame: Up to 5 years
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42574969 ↗
    Study completion Jul 24, 2027→Sep 28, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective response rateResponse Rate (ORR)Time frame: Within 9 months of initiating study treatment
    Secondary outcomes 4 edited, 1 removed
    What changed in the outcomes
    • EditedDuration of responseResponseTime frame: From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years → Within 9 months of initiating study treatment
    • EditedProgression-free survivalSurvival (PFS)Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact with known progression free status if neither progression nor death has occurred, assessed up to 5 years → up to 22 months
    • EditedOverall survivalSurvival (OS)Time frame: From study entry to time of death or the date of last contact, assessed up to 5 years → up to 22 months
    • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 5 years → Adverse Events were assessed up to 9 months, All Cause Mortality was assessed up to 22 months.
    • Removedother outcomeBiomarkers predictive of responseTime frame: Up to 5 years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06169124
Collaborators
NRG Oncology
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Feb 8, 2024
Primary completion
Feb 10, 2026
Completion
Sep 28, 2026
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Elizabeth Hopp
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darolutamide · Exemestane · Leuprolide

Start the discussion